Anti-CD20-based therapy of B cell lymphoma: state of the art

Leukemia. 2002 Oct;16(10):2004-15. doi: 10.1038/sj.leu.2402639.


Over the last 5 years, studies applying the chimeric anti-CD20 MAb have renewed enthusiasm and triggered world-wide application of anti-CD20 MAb-based therapies in B cell non-Hodgkin's lymphoma (NHL). Native chimeric anti-CD20 and isotope-labeled murine anti-CD20 MAbs are currently employed with encouraging results as monotherapy or in combination with conventional chemotherapy and in consolidation of remission after treatments with curative intent (ie after/ in combination with high-dose chemotherapy and hematopoietic stem cell rescue). On the available experience, anti-CD20 MAb-based therapeutic strategies will be increasingly integrated in the treatment of B cell NHL and related malignancies.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antigens, CD20 / immunology*
  • Antineoplastic Agents / therapeutic use
  • Combined Modality Therapy
  • Humans
  • Lymphoma, B-Cell / drug therapy
  • Lymphoma, B-Cell / therapy*


  • Antibodies, Monoclonal
  • Antigens, CD20
  • Antineoplastic Agents